Background image


Most Recent:

Title: Xylazine – Background, Prevalence, and Co-Exposure Research in Hair in a High-Risk Population

ToxTime Event June 20, 2024 at 1:00 PM CSTIn this presentation, USDTL’s Andre Sukta, Research and Development Projects Manager, will go through the background of xylazine, why it was developed, what it is primarily used for, and the prevalence and co-exposure of it being used in a human population.

A recording of the presentation and a certificate of attendance will be available 24-48 hours after completion of the webinar. You must be signed up for our mailing list to receive a certificate.

Click to Register Today



Watch Our Past Events:

Reducing Bias in Healthcare Starts with Destigmatizing Language

Fetal Alcohol Spectrum Disorders: Components & Services Overview
Kratom: Should You Be Concerned?
Collection Site Panelist Discussion: Legal Professionals & Social Workers
Protecting Your Hospital with Forensic Newborn Drug Testing
The Detection of Buprenorphine in Hair
Newborn Toxicology: A Review and Recent Developments
The Detection of Fentanyl in Hair
Detecting Illicit Fentanyl in Newborns
Understanding Toxicology Reports: Confirmations, Cutoffs, and the Quantitative Values
Newborn Alcohol Biomarkers
Hair and Nail Testing: What’s the Difference?
Drug Trends and Concerns Regarding NAS
Environmental Exposure Drug Testing 101 (ChildGuard®)
Missed Opportunities in Newborn Drug Testing
Phosphatidylethanol Recent Developments
Protecting & Enriching Lives
FASD & Newborn Alcohol Biomarker Testing
Phosphatidylethanol (PEth) Overview
Meconium & Umbilical Cord Overview
Gabapentin Overview

Contact USDTL